Sign in
OSTX Stock Price, Chart, Stats & News
OS Therapies Incorporated
Save
OS Therapies Incorporated (OSTX) does not currently pay a dividend.
–
Market cap
–
Current P/E
1.66x
Forward P/E
OSTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -204.22% |
ROE | -567.59% |
D/E | – |
Interest coverage ratio | -2605.11x |
OSTX valuation
P/E | – |
P/S | – |
P/B | 9.57x |
P/CF | -3.50x |
P/FCF | -3.72x |
P/OCF | -3.50x |
PEG | 0.48x |
EV multiple | -2.86x |
About
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Similar securities
Based on sector and market capitalization
Report issue